返回 Agenda
Session 9: FDA's Actions on the Original IND and Future Amendments
Session Chair(s)
Elliott Berger, PhD, MS
President
ETB Regualtory Consulting, United States
- FDA’s Review of an IND
- Clinical Holds: Basis for imposition and process for removal